Table 1.
Least square means (LSMean) at cycle 6 from the mixed-effects model for repeated measures (MMRM) analysis
| LCSS item | Cisplatin | Pemetrexed/cisplatin | Difference | ||
|---|---|---|---|---|---|
| LSMean | SE | LSMean | SE | P-value | |
| Anorexia | 32.4 | 2.2 | 32.3 | 1.9 | 0.961 |
| Cough | 11.8 | 1.5 | 10.5 | 1.3 | 0.523 |
| Dyspnea | 36.9 | 2.0 | 30.9 | 1.7 | 0.023 |
| Fatigue | 44.7 | 2.1 | 41.3 | 1.8 | 0.218 |
| Pain | 28.7 | 2.0 | 25.0 | 1.7 | 0.157 |
| Interference | 48.5 | 2.0 | 44.5 | 1.8 | 0.136 |
| QoL | 47.3 | 2.0 | 43.6 | 1.7 | 0.164 |
| Symptoms | 38.9 | 2.0 | 35.4 | 1.7 | 0.194 |
| ASBI5 | 31.6 | 1.4 | 28.3 | 1.2 | 0.076 |
| ASBI8 | 36.9 | 1.4 | 33.2 | 1.3 | 0.053 |
LCSS Lung Cancer Symptom Scale, ASBI5 the mean of the five symptom items (anorexia, cough, dyspnea, fatigue, and pain), ASBI8 the mean of the five symptom items and the three global items (interference, QoL, and symptoms). SE standard error